In June 2022, the FDA required the addition of ‘suicidal ideation and behavior’ to the Propecia (finasteride 1 mg) label. In July, France’s national drug regulator ANSM added materials to help patients better understand the risks of finasteride.
SUMMARY The Sexual Medicine Society of North America hosted a webinar including a talk about sexual dysfunction induced by finasteride and SSRIs. A study by Baylor researchers finding altered gene expression in post-finasteride patients was published in the Journal of Sexual Medicine. The FDA added a new adverse event to the Propecia label: Hematospermia. The … Read more